Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Anti-Hypertensive Drugs - GCC

GCC
  • The Anti-Hypertensive Drugs market in GCC is expected to witness substantial growth in the coming years.
  • According to projections, the revenue is estimated to reach US$187.20m by 2024.
  • Furthermore, it is anticipated that the market will exhibit a steady annual growth rate (CAGR 2024-2029) of -0.02%, leading to a market volume of US$187.00m by 2029.
  • When compared globally, United States is expected to generate the highest revenue in this market, with an estimated US$12.29bn in 2024.
  • The demand for anti-hypertensive drugs in the GCC is rising steadily due to the high prevalence of hypertension among the population.

Definition:
Anti-hypertensive drugs are used to treat high blood pressure. This market covers different types of anti-hypertensive drugs, such as calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), beta blockers, and thiazide diuretics.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim

In-Scope

  • Drugs to treat high blood pressure
  • Pulmonary hypertension

Out-Of-Scope

  • Anti-coagulants
  • Anti-fibrinolytics
  • Cardiology devices
  • Blood pressure meters
Anti-Hypertensive Drugs: market data & analysis - Cover

Market Insights report

Anti-Hypertensive Drugs: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The Anti-Hypertensive Drugs market in GCC has been experiencing significant growth in recent years.

    Customer preferences:
    The rising prevalence of hypertension in GCC countries has led to an increase in demand for Anti-Hypertensive Drugs. In addition, the aging population and unhealthy lifestyle habits such as lack of physical activity, smoking, and unhealthy diets have contributed to the growth of the market.

    Trends in the market:
    Saudi Arabia is the largest market for Anti-Hypertensive Drugs in the GCC region, followed by the UAE and Qatar. The market is dominated by branded drugs, with a preference for fixed-dose combination products. However, there is also a growing demand for generic drugs due to their affordability. The market is expected to continue growing due to the increasing prevalence of hypertension and the introduction of new drugs.

    Local special circumstances:
    In GCC countries, there is a high prevalence of obesity, which is a major risk factor for hypertension. This has led to a growing demand for Anti-Hypertensive Drugs in the region. In addition, the GCC region has a high-income population, which has contributed to the growth of the market.

    Underlying macroeconomic factors:
    The healthcare sector in GCC countries is undergoing significant development, with increased investment in healthcare infrastructure and the introduction of health insurance schemes. This has led to improved access to healthcare services and increased demand for drugs, including Anti-Hypertensive Drugs. In addition, the GCC region has a growing population, which is expected to contribute to the growth of the market in the coming years.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Anti-Hypertensive Drugs: market data & analysis - BackgroundAnti-Hypertensive Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.